We read with interest the study by Cheung et al confirming the risk of proton pump inhibitors (PPIs) for gastric cancer regarding the patients after Helicobacter pylori (H. pylori) eradication with long-term PPIs use.1 Most concerns about the safety of PPIs pertain to the increased risk for enteric infections, fractures and nutritional deficiencies.2 To date, the association of PPIs use and risk of gastric cancer is still controversial in patients with gastro-oesophageal reflux diseases (GERD). For GERD, PPIs are the mainstay of treatment in the management of patients with acid-related disorders.3 Thus, patients with GERD usually take long-term PPIs,and possibly carry the risk of gastric cancer. In the present study, we performed a case–control study to investigate the association of PPIs use and risk of gastric cancer using data from a nationwide population database, the National Health Insurance Research Database (NHIRD) in Taiwan.4 This study also used a subdataset of the NHIRD, which comprises one million randomly sampled beneficiaries enrolled in the NHI programme in 2000 (Longitudinal Health Insurance Database …

中文翻译：

---

GERD患者使用质子泵抑制剂与胃癌风险之间的关系

我们饶有兴趣地阅读了 Cheung 等人的研究，该研究证实了长期使用 PPI 根除幽门螺杆菌 (H. pylori) 后患者使用质子泵抑制剂 (PPI) 治疗胃癌的风险。 1 最担心 PPI 的安全性与肠道感染、骨折和营养缺乏风险增加有关。2 迄今为止，胃食管反流病 (GERD) 患者中 PPI 的使用与胃癌风险之间的关联仍存在争议。对于 GERD，PPI 是治疗胃酸相关疾病患者的主要治疗方法 3。因此，GERD 患者通常长期服用 PPI，并可能有患胃癌的风险。在目前的研究中，